Investment
Features
FeesSafety
Academy
More
Pluang+

Compare W W Grainger Inc (GWW) vs uniQure N.V. Ordinary Shares (QURE) Price & Performance

W W Grainger IncTrade
uniQure N.V. Ordinary SharesTrade

Price performance (Past 24H)

Key statistics

W W Grainger Inc vs uniQure N.V. Ordinary Shares — how do they compare? W W Grainger Inc trades at $1,330.68 (market cap $62.41B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: W W Grainger Inc is far larger — about 42.2× uniQure N.V. Ordinary Shares's market cap, and W W Grainger Inc pays a 0.75% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold W W Grainger Inc for 26 Days and uniQure N.V. Ordinary Shares for 0 Days on average.

GWWQURE
Market Cap
$62.41B$1.48B
Volume
284,7152,488,780
Sector
IndustrialsHealth
52-Week High
$1.40K$70.59
52-Week Low
$918.18$9.03
Typical Hold Time
26 Days0 Days
Enterprise Value
$64.62B$728.62M
Dividend Yield
0.75%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

W W Grainger Inc

GWW trades at $1,325.10, up 1.41% today, with a bullish technical signal and strong fundamentals including a 47.92% ROE and 9.92% net income margin. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a solid dividend as a Dividend King. Institutional buying and positive analyst coverage support the stock's momentum.

Outlook remains positive with a consensus price target of $1,310, though high valuation multiples and competitive pressures pose risks. Earnings growth and market share gains in industrial distribution are key drivers for continued upside.

uniQure N.V. Ordinary Shares

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GWW
100% Buy0% Sell
Avg holding period · 26 Days
QURE
100% Buy0% Sell
Avg holding period · 0 Days

About W W Grainger Inc

Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.

Read more on GWW →

About uniQure N.V. Ordinary Shares

uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.

Read more on QURE →